Intuitive Surgical Reports Record Performance, Beats Estimates by Over 3%

Trending News 🌥️

The company posted non-GAAP earnings per share of $1.23, beating the estimates by $0.03, while revenue of $1.69B was $100M higher than expected. This is the highest quarterly performance that Intuitive Surgical ($NASDAQ:ISRG) has reported in its history. Its products provide surgeons with a robotic platform that allows them to perform minimally invasive surgery using advanced technologies such as 3D visualization and haptic feedback.

Intuitive Surgical’s products are used in a variety of surgical procedures such as hysterectomy, prostatectomy, and general surgery. Intuitive Surgical’s stock is up significantly since the beginning of the year and looks set to continue its growth trajectory in the coming quarters.

Share Price

INTUITIVE SURGICAL reported record performance on Tuesday, with their stock opening at $270.0 and closing at $269.3, representing a 0.1% increase from the previous closing price of 268.9. This performance beat estimates by over 3%, indicating that INTUITIVE SURGICAL is continuing to experience strong financial growth. The increased performance is attributed to rising demand for the company’s robotic-assisted surgeries, which have proven to be more efficient and accurate than traditional surgical methods. INTUITIVE SURGICAL is well-positioned for further success in the coming months as the company continues to provide innovative and technologically advanced solutions for medical procedures. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Intuitive Surgical. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Intuitive Surgical. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Intuitive Surgical. More…

Key Ratios Snapshot

Some of the financial key ratios for Intuitive Surgical are shown below. More…

Analysis

At GoodWhale, we recently conducted an analysis of INTUITIVE SURGICAL‘s wellbeing. Our Risk Rating system gave INTUITIVE SURGICAL a medium risk investment rating, taking into account both the financial and business aspects. However, upon further investigation, our team has identified three risk warnings in INTUITIVE SURGICAL’s income sheet, balance sheet, and non-financial elements. To gain access to the risk warnings, please register with GoodWhale. Our team is dedicated to helping you make informed decisions about your investments and will be happy to provide more detailed insights on INTUITIVE SURGICAL. More…

Peers

The company’s da Vinci surgical system consists of a surgeon’s console, a patient-side cart and a vision system. The company’s competitors in the robotic surgery market include Stryker Corp, Medtronic PLC, Becton, Dickinson and Co.

– Stryker Corp ($NYSE:SYK)

With a market capitalization of $84.98 billion as of 2022, Stryker Corporation is one of the world’s leading medical technology companies. Headquartered in Kalamazoo, Michigan, the company offers a broad range of products and services in orthopedics, medical and surgical, and neurotechnology and spine that help improve patient care and quality of life. The company’s products include implants used in hip, knee and shoulder replacements, as well as instrumentation and software used in operating rooms and for patient rehabilitation. In addition, Stryker offers a wide range of products and services for minimally invasive surgery, including robotic-assisted surgery systems. The company’s return on equity was 10.79% as of 2022.

– Medtronic PLC ($NYSE:MDT)

Medtronic PLC is a medical technology company that develops and produces a variety of medical devices and software products. The company has a market capitalization of 112.31 billion as of 2022 and a return on equity of 7.49%. Medtronic PLC’s products are used in a wide range of medical procedures, including cardiovascular, neurological, and orthopedic procedures. The company’s products are sold in over 150 countries around the world.

– Becton, Dickinson and Co ($NYSE:BDX)

Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, laboratory equipment, and diagnostic products. The company has a market cap of 64.37B as of 2022 and a return on equity of 6.42%. The company’s products are used in a variety of medical procedures, including blood transfusions, IV start kits, and diabetes care.

Summary

Intuitive Surgical Inc. has seen strong financial results in its most recent quarter. The company reported a non-GAAP earnings per share (EPS) of $1.23, exceeding analyst expectations by $0.03. Revenue for the quarter totaled $1.69B, beating estimates by $100M. These positive results indicate that Intuitive Surgical is performing well and that investors should remain optimistic about future growth prospects.